

**From:** Parmelee, Steve  
**To:** [Trials](#)  
**Cc:** [Rosato, Michael](#); [Mills, Jad](#); ["TRea@Crowell.com"](#); ["DYellin@Crowell.com"](#); ["SLentz@Crowell.com"](#); ["TLiu@agpharm.com"](#); ["amanda.hollis@kirkland.com"](#); ["egoryunov@kirkland.com"](#); ["gregory.springsted@kirkland.com"](#); ["spark@winston.com"](#); ["CKlein@winston.com"](#); ["jlove@gibsondunn.com"](#); ["rtrenchard@gibsondunn.com"](#)  
**Subject:** IPR2017-00854 | Apotex Inc. et al. v. Novartis A.G. |  
**Date:** Friday, July 27, 2018 3:41:00 PM

---

Trials,

Petitioners Apotex Inc. and Apotex Corp. filed a notice of appeal yesterday, July 26, 2018, in E2E, but the Federal Circuit's PACER payment processing system was unable to complete payment yesterday. The PACER payment processing system is now working and Petitioners Apotex Inc. and Apotex Corp. have re-filed the notice of appeal today in E2E, with today's date, and have completed the necessary payment. The notice of appeal filed yesterday in E2E in this matter can be expunged or disregarded, at the Board's option.

Respectfully submitted,

Steven W. Parmelee  
Wilson Sonsini Goodrich & Rosati  
701 Fifth Avenue, Suite 5100  
Seattle, WA 98104  
206-883-2542 Direct

This email and any attachments thereto may contain private, confidential, and privileged material for the sole use of the intended recipient. Any review, copying, or distribution of this email (or any attachments thereto) by others is strictly prohibited. If you are not the intended recipient, please contact the sender immediately and permanently delete the original and any copies of this email and any attachments thereto.